| Walnut (Juglans regia) — The edible seed of the Persian or English walnut tree, classified as a whole-food source of polyunsaturated fatty acids, polyphenols, phytosterols, tocopherols, and dietary fibre. Common abbreviation: WN. Walnuts provide approximately 2.5 g of alpha-linolenic acid (ALA) per 28 g serving and contain ellagitannins, particularly pedunculagin, that can be metabolized to ellagic acid and gut-microbiota-derived urolithins. Experimental studies suggest antiproliferative, anti-inflammatory, antiangiogenic, and microbiome-mediated activities, but walnuts are not an established cancer treatment.
Walnut (Juglans regia) — Bioactive Ingredients
Approximate composition per 100 g of raw English walnut kernels. Quantities vary by cultivar, growing conditions, storage, and analytical method. Components are ranked by nutritional abundance and potential biological relevance. Hyperlinks connect to existing Nestronics database entries.
| Rank |
Active Ingredient |
Class |
Amount per 100 g |
Primary Biological Relevance |
| 1 |
Alpha-linolenic acid (ALA) |
Omega-3 fatty acid |
8,000–10,000 mg |
Inflammatory lipid signaling, PPAR regulation, cardiovascular effects; experimental anticancer activity. |
| 2 |
Linoleic acid (LA) |
Omega-6 fatty acid |
35,000–40,000 mg |
Essential membrane lipid and precursor for lipid mediators; effects depend on metabolic context. |
| 3 |
Oleic acid |
Omega-9 fatty acid |
8,000–10,000 mg |
Membrane lipid composition, metabolic regulation and lipid signaling. |
| 4 |
Polyphenols |
Phenolic compound class |
Highly variable; several hundred mg to over 1,000 mg total phenolic equivalents |
Antioxidant, inflammatory and microbiome-mediated activities. Total phenolics are assay-dependent and not the sum of individual compounds. |
| 5 |
Ellagitannins, including pedunculagin |
Hydrolysable tannins |
Variable; no reliable universal value |
Major walnut phenolics; precursors of ellagic acid and microbiome-derived urolithins. |
| 6 |
Ellagic acid |
Phenolic acid derivative |
Variable; substantial fraction occurs in bound ellagitannins |
Experimental antiproliferative and inflammatory signaling effects; limited systemic availability. |
| 7 |
Urolithins, including Urolithin A |
Microbial polyphenol metabolites |
Not naturally present in meaningful amounts |
Produced after ingestion by suitable gut microbiota; studied for mitophagy, mitochondrial function and cancer-cell signaling. |
| 8 |
Beta-sitosterol |
Phytosterol |
Approximately 60–120 mg |
Cholesterol absorption modulation and experimental antiproliferative effects. |
| 9 |
Campesterol and stigmasterol |
Phytosterols |
Minor constituents; variable |
Contribute to the phytosterol fraction and sterol-mediated metabolic effects. |
| 10 |
Vitamin E, mainly gamma-tocopherol |
Tocopherols |
Approximately 15–25 mg gamma-tocopherol; about 0.7 mg alpha-tocopherol |
Lipid antioxidant protection and modulation of oxidative stress. Gamma-tocopherol is not equivalent to alpha-tocopherol for vitamin E activity. |
| 11 |
Quercetin |
Flavonol |
Trace to low mg amounts; variable |
Inflammatory signaling, kinase modulation and experimental antiproliferative effects. |
| 12 |
Myricetin |
Flavonol |
Trace; variable |
Antioxidant and cell-signaling effects in experimental systems. |
| 13 |
Gallic acid |
Phenolic acid |
Variable; also present in bound phenolic structures |
Antioxidant and experimental anti-inflammatory activity. |
| 14 |
Caffeic acid |
Phenolic acid |
Trace; variable |
Phenolic antioxidant and inflammatory signaling effects. |
| 15 |
Phytic acid (IP6) |
Inositol phosphate |
Approximately 500–2,000 mg |
Mineral chelation, antioxidant chemistry and experimental cancer-related signaling; may reduce absorption of some minerals. |
| 16 |
Dietary fibre |
Complex carbohydrates |
Approximately 6,700 mg |
Microbiome fermentation, short-chain fatty acid production and gastrointestinal metabolic effects. |
| 17 |
Melatonin |
Indoleamine |
Trace; ng/g-range concentrations reported |
Antioxidant and circadian signaling; dietary exposure is much lower than common supplemental doses. |
| 18 |
Magnesium |
Mineral |
158 mg |
ATP-dependent enzymes, glucose metabolism, neuronal function and cellular signaling. |
| 19 |
Zinc |
Trace mineral |
3.1 mg |
Immune regulation, DNA repair and antioxidant enzyme functions. |
| 20 |
Copper |
Trace mineral |
1.6 mg |
Oxidative enzyme activity, mitochondrial respiration and connective-tissue metabolism. |
| 21 |
Manganese |
Trace mineral |
3.4 mg |
MnSOD cofactor and mitochondrial antioxidant enzyme function. |
| 22 |
Selenium |
Trace mineral |
Approximately 4.9 micrograms |
Selenoproteins, glutathione peroxidase and thyroid metabolism. |
| 23 |
Vitamin B6 |
Vitamin |
0.54 mg |
Amino acid metabolism and neurotransmitter synthesis. |
| 24 |
Folate (Vitamin B9) |
Vitamin |
98 micrograms |
One-carbon metabolism, nucleotide synthesis and methylation. |
| 25 |
Vitamin B1 (Thiamine) |
Vitamin |
0.34 mg |
Carbohydrate oxidation and mitochondrial energy metabolism. |
| 26 |
Vitamin B3 (Niacin) |
Vitamin |
1.1 mg |
NAD/NADP coenzyme synthesis and cellular redox metabolism. |
Interpretation: Fatty acids are the quantitatively dominant bioactive constituents. Ellagitannins and their metabolites are particularly relevant to experimental anticancer mechanisms, but urolithin production is microbiome-dependent. Whole-walnut phytochemical composition varies considerably, so trace-compound or total-phenolic values should not be interpreted as standardized dietary doses.
Database note: The unlinked constituents beta-sitosterol, gamma-tocopherol, linoleic acid and pedunculagin may warrant individual Compound entries if sufficient mechanistic research is collected. Juglone is primarily associated with other walnut tissues and should not be treated as a major constituent of ordinary edible walnut kernels.
Primary mechanisms (ranked):
- Omega-3 lipid signaling: ALA and associated unsaturated fatty acids modulate lipid metabolism, inflammatory mediators, and nuclear receptors including PPAR and FXR, with antiproliferative effects demonstrated in experimental cancer models.
- Ellagitannin–ellagic acid–urolithin metabolism: Walnut polyphenols undergo gastrointestinal and microbial biotransformation, generating metabolites with potential anti-inflammatory, antiproliferative, and mitochondrial regulatory effects.
- Cell proliferation and apoptosis: Whole-walnut diets and walnut-derived constituents alter cancer-associated gene expression, reduce proliferation, and may promote apoptosis in selected experimental models.
- Gut microbiome and short-chain fatty acids: Walnut fibre and polyphenols modify microbial ecology and microbial metabolites, potentially affecting intestinal inflammation and colorectal carcinogenesis.
- Angiogenesis and metastatic signaling: Experimental walnut diets and individual phytosterols may suppress VEGF-related angiogenesis, AKT-associated survival signaling, and invasion-related pathways (model-dependent).
- Oxidative stress and inflammatory regulation: Walnut phenolics and tocopherols may reduce oxidative damage and modify inflammatory signaling; NRF2 involvement is secondary and not established as a primary whole-walnut anticancer mechanism.
Bioavailability / PK relevance: ALA is absorbed through conventional dietary lipid pathways, while ellagitannins have limited direct systemic availability. Ellagic acid undergoes extensive metabolism, and generation of urolithins depends strongly on individual gut microbiota. Circulating metabolites are frequently conjugated, making direct extrapolation from purified compounds uncertain. Whole-walnut interventions commonly use approximately 28–75 g/day.
In-vitro vs systemic exposure relevance: Direct application of concentrated walnut extracts, free ellagic acid, or purified urolithins can produce exposures substantially different from those achieved after ordinary walnut consumption. Many experimental anticancer concentrations are not demonstrated to be achievable as free circulating compounds through dietary walnut intake. Whole-food effects also involve chronic nutritional and microbiome changes rather than a single circulating drug concentration.
Clinical evidence status: Preclinical: multiple positive cell and animal studies involving breast, prostate, colorectal, and renal cancers. Small human: a randomized pilot study in 10 breast cancer patients identified potentially favourable tumour gene-expression changes after approximately two weeks of walnut consumption. RCT: human nutritional trials exist, but convincing cancer-incidence, survival, or tumour-response efficacy has not been established. Adjunct use: reasonable as part of a healthy dietary pattern, but not validated as an anticancer therapy.
Safety / interpretation: Walnuts are generally safe as food but must be avoided with walnut or relevant tree-nut allergy. They are energy-dense, providing approximately 185 kcal per 28 g, and intake may require dietary substitution rather than simple addition. Whole-walnut effects should not be equated with results from concentrated walnut hull extracts, purified ellagic acid, or isolated urolithin supplements.
Walnut: Mechanistic Effects Relevant to Cancer
| Rank |
Pathway / Axis |
Cancer Cells |
Normal Cells |
TSF |
Primary Effect |
Notes / Interpretation |
| 1 |
ALA / PPAR / FXR lipid signaling |
↓ Proliferation (model-dependent) |
↔ / ↑ Lipid regulation |
G |
Altered nuclear receptor and lipid signaling |
Walnut oil extracts, ALA, and beta-sitosterol affect breast cancer proliferation and FXR signaling. Evidence primarily preclinical. |
| 2 |
Ellagitannins / Ellagic acid / Urolithins |
↓ Proliferation; ↑ apoptosis (model-dependent) |
↑ Metabolite-mediated signaling |
G |
Microbiome-dependent polyphenol bioactivity |
Pedunculagin-derived metabolites may contribute to anticancer effects. Urolithin production varies substantially between individuals. |
| 3 |
Tumour proliferation and survival pathways |
↓ Proliferation-associated gene expression |
↔ / context-dependent |
G |
Reduced tumour growth potential |
Small human breast cancer pilot reported favourable gene-expression changes, without demonstrating improved clinical outcomes. |
| 4 |
Gut microbiome / SCFA metabolism |
↓ Pro-tumour intestinal environment (indirect) |
↑ Beneficial microbial metabolites |
G |
Changes intestinal microbial ecology |
Human RCTs demonstrate microbiome changes. Cancer protection remains inferential. |
| 5 |
Secondary bile acids / Intestinal inflammation |
↓ Potential tumour-promoting exposure |
↓ Proinflammatory bile acid exposure |
G |
Reduced intestinal secondary bile acids |
42 g/day walnuts reduced fecal deoxycholic acid and lithocholic acid in a controlled human trial. |
| 6 |
PI3K / AKT survival signaling |
↓ pAKT (model-dependent) |
↔ / context-dependent |
G |
Potential reduction in survival signaling |
Supported more directly by isolated phytosterol experiments than whole-walnut clinical studies. |
| 7 |
VEGF / Angiogenesis |
↓ Angiogenic signaling (model-dependent) |
↔ / context-dependent |
G |
Potential suppression of tumour vascularization |
Reported in experimental walnut-fed tumour models and phytosterol investigations. |
| 8 |
Apoptosis / Cell-cycle regulation |
↑ Apoptotic responses; ↓ proliferation (model-dependent) |
↔ / context-dependent |
G |
Reduced tumour-cell viability |
Whole-walnut dietary studies support antitumour effects in mice; individual pathway responses vary across models. |
| 9 |
ROS / Oxidative stress regulation |
↔ ROS; context-dependent |
↓ Oxidative damage (context-dependent) |
R/G |
Antioxidant and lipid-peroxidation regulation |
Walnut constituents have antioxidant activity, but generalized ROS suppression in cancer cells is not established. |
| 10 |
NRF2 / Antioxidant response |
↔ / context-dependent |
↑ Cytoprotective signaling (possible) |
G |
Secondary antioxidant response |
Constituent-level mechanisms should not be attributed directly to ordinary walnut consumption without confirmation. |
| 11 |
Inflammatory lipid mediators |
↓ Inflammatory support (indirect) |
↓ Proinflammatory lipid mediators (model-dependent) |
G |
Altered lipid-derived inflammatory signaling |
Walnut-enriched diets modify tissue lipid metabolites in animal studies. Human cancer significance remains uncertain. |
| 12 |
Clinical Translation Constraint |
↔ Clinical anticancer efficacy unproven |
Generally well tolerated as food |
G |
Dietary exposure and evidence limitations |
Variable urolithin production, low unconjugated polyphenol exposure, heterogeneous food composition, small cancer trials, and lack of validated therapeutic endpoints. |
P: 0–30 min R: 30 min–3 hr G: >3 hr
|